Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised... by Kristeleit, Rebecca, MD, Lisyanskaya, Alla, MD, Fedenko, Alexander, MD, Dvorkin, Mikhail, MD, de Melo, Andreia Cristina, MD, Shparyk, Yaroslav, Prof, Rakhmatullina, Irina, Prof, Bondarenko, Igor, Prof, Colombo, Nicoletta, Prof, Svintsitskiy, Valentyn, MD, Biela, Luciano, MD, Nechaeva, Marina, MD, Lorusso, Domenica, Prof, Scambia, Giovanni, Prof, Cibula, David, MD, Póka, Róbert, Prof, Oaknin, Ana, MD, Safra, Tamar, MD, Mackowiak-Matejczyk, Beata, MD, Ma, Ling, MD, Thomas, Daleen, BSc, Lin, Kevin K, PhD, McLachlan, Karen, PhD, Goble, Sandra, MSc, Oza, Amit M, Prof

Get full text

Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study by Bagnoli, Marina, PhD, Canevari, Silvana, PhD, Califano, Daniela, PhD, Losito, Simona, MD, Maio, Massimo Di, Prof, Raspagliesi, Francesco, MD, Carcangiu, Maria Luisa, MD, Toffoli, Giuseppe, MD, Cecchin, Erika, PhD, Sorio, Roberto, MD, Canzonieri, Vincenzo, MD, Russo, Daniela, PhD, Scognamiglio, Giosué, PhD, Chiappetta, Gennaro, PhD, Baldassarre, Gustavo, MD, Lorusso, Domenica, MD, Scambia, Giovanni, Prof, Zannoni, Gian Franco, Prof, Savarese, Antonella, MD, Carosi, Mariantonia, MD, Scollo, Paolo, MD, Breda, Enrico, MD, Murgia, Viviana, MD, Perrone, Francesco, MD, Pignata, Sandro, MD, De Cecco, Loris, PhD, Mezzanzanica, Delia, Dr

Get full text

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial by Pignata, Sandro, Dr, Scambia, Giovanni, Prof, Katsaros, Dionyssios, Prof, Gallo, Ciro, Prof, Pujade-Lauraine, Eric, Prof, De Placido, Sabino, Prof, Bologna, Alessandra, MD, Weber, Beatrice, MD, Raspagliesi, Francesco, MD, Panici, Pierluigi Benedetti, Prof, Cormio, Gennaro, MD, Sorio, Roberto, MD, Cavazzini, Maria Giovanna, MD, Ferrandina, Gabriella, MD, Breda, Enrico, MD, Murgia, Viviana, MD, Sacco, Cosimo, MD, Cinieri, Saverio, MD, Salutari, Vanda, MD, Ricci, Caterina, MD, Pisano, Carmela, MD, Greggi, Stefano, MD, Lauria, Rossella, MD, Lorusso, Domenica, MD, Marchetti, Claudia, MD, Selvaggi, Luigi, Prof, Signoriello, Simona, PhD, Piccirillo, Maria Carmela, MD, Di Maio, Massimo, MD, Perrone, Francesco, MD

Get full text

Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, ph... by Ledermann, Jonathan A, Prof, Oza, Amit M, MD, Lorusso, Domenica, MD, Aghajanian, Carol, MD, Oaknin, Ana, MD, Dean, Andrew, MD, Colombo, Nicoletta, Prof, Weberpals, Johanne I, MD, Clamp, Andrew R, PhD, Scambia, Giovanni, MD, Leary, Alexandra, MD, Holloway, Robert W, MD, Gancedo, Margarita Amenedo, MD, Fong, Peter C, FRACP, Goh, Jeffrey C, FRACP, O'Malley, David M, MD, Armstrong, Deborah K, MD, Banerjee, Susana, PhD, García-Donas, Jesus, MD, Swisher, Elizabeth M, Prof, Cameron, Terri, MSc, Maloney, Lara, BA, Goble, Sandra, MS, Coleman, Robert L, MD

Get full text

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial by Pignata, Sandro, MD, Lorusso, Domenica, MD, Joly, Florence, MD, Gallo, Ciro, Prof, Colombo, Nicoletta, Prof, Sessa, Cristiana, Prof, Bamias, Aristotelis, Prof, Salutari, Vanda, MD, Selle, Frédèric, MD, Frezzini, Simona, MD, De Giorgi, Ugo, MD, Pautier, Patricia, MD, Bologna, Alessandra, MD, Orditura, Michele, Prof, Dubot, Coraline, MD, Gadducci, Angiolo, Prof, Mammoliti, Serafina, MD, Ray-Coquard, Isabelle, Prof, Zafarana, Elena, MD, Breda, Enrico, MD, Favier, Laure, MD, Ardizzoia, Antonio, MD, Cinieri, Saverio, Prof, Largillier, Rémy, MD, Sambataro, Daniela, MD, Guardiola, Emmanuel, MD, Lauria, Rossella, MD, Pisano, Carmela, MD, Raspagliesi, Francesco, MD, Scambia, Giovanni, MD, Daniele, Gennaro, MD, Perrone, Francesco, MD

Get full text

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 t... by Pignata, Sandro, Dr, Lorusso, Domenica, MD, Scambia, Giovanni, Prof, Sambataro, Daniela, MD, Tamberi, Stefano, MD, Cinieri, Saverio, MD, Mosconi, Anna M, MD, Orditura, Michele, MD, Brandes, Alba A, MD, Arcangeli, Valentina, MD, Panici, Pierluigi Beneditti, Prof, Pisano, Carmela, MD, Cecere, Sabrina C, MD, Di Napoli, Marilena, MD, Raspagliesi, Francesco, MD, Maltese, Giuseppa, MD, Salutari, Vanda, MD, Ricci, Caterina, MD, Daniele, Gennaro, MD, Piccirillo, Maria Carmela, MD, Di Maio, Massimo, MD, Gallo, Ciro, Prof, Perrone, Francesco, MD

Get full text

Second-line dovitinib (TKI258) in patients with FGFR2 -mutated or FGFR2 -non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage,... by Konecny, Gottfried E, Dr, Finkler, Neil, Prof, Garcia, Agustin A, MD, Lorusso, Domenica, MD, Lee, Paula S, MD, Rocconi, Rodney P, MD, Fong, Peter C, MBBS, Squires, Matt, PhD, Mishra, Kaushal, PhD, Upalawanna, Allison, PharmD, Wang, Yongyu, MD, Kristeleit, Rebecca, MD

Get full text

A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in... by Makker, Vicky, MD, Colombo, Nicoletta, MD, Herráez, Antonio Casado, MD, Santin, Alessandro, MD, Colomba, Emeline, MD, Miller, David, MD, FACOG, FACS, Fujiwara, Keiichi, MD, PhD, Pignata, Sandro, MD, PhD, Baron-Hay, Sally, MBBS, FRACP, Ray-Coquard, Isabelle, Prof, Shapira-Frommer, Ronnie, MD, Ushijima, Kimio, Sakata, Jun, MD, PhD, Yonemori, Kan, MD, Kim, Yong Man, MD, Guerra, Eva, MD, Sanli, Ulus, MD, McCormack, Mary, PhD MBBS FRCR, Huang, Jie, Smith, Alan, Keefe, Stephen, MD, Dutta, Lea, PharmD, Orlowski, Robert, MD, Lorusso, Domenica, MD, PhD

Get full text

Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 tria... by Pujade-Lauraine, Eric, MD, PhD, Brown, Jessica, MD PhD, Barnicle, Alan, Rowe, Phil, MSc, Lao-Sirieix, Pierre, PhD, Criscione, Steven, du Bois, Andreas, MD, PhD, Lorusso, Domenica, MD, Romero, Ignacio, MD, Petru, Edgar, MD, Yoshida, Hiroyuki, MD, PhD, Vergote, Ignace, MD, PhD, Colombo, Nicoletta, MD, Hietanen, Sakari, MD, Provansal, Magali, MD, Schmalfeldt, Barbara, Pignata, Sandro, MD, PhD, Martin-Lorente, Cristina, MD, Berton, Dominique, MD, Runnebaum, Ingo, MD, Ray-Coquard, Isabelle, Prof

Get full text